When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight ...

Viking on Thursday reported a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share. ・Morgan ...

The first thing you notice about the Viking 44 Open is her racy, eye-pleasing and proportional profile. From that slightly raked bow to her gently sloping sheer, and the way the wraparound windshield ...

Viking (NYSE:VIK) priced its secondary offering of an aggregate of ~30.53M ordinary shares at a public offering price of $44.20 per share. The offering is expected to close on May 29, 2025. The ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.

Viking Holdings Ltd. has set terms for its initial public offering, which puts the cruise operator on a heading to be valued at up to $10.8 billion. The Bermuda-based company said 44 million shares ...

Subscribe to Marlin magazine and get a year of highly collectible, keepsake editions – plus access to the digital edition and archives. Sign up for the free Marlin email newsletter. This year’s ...

A Viking river cruise ship heading north up the Mississippi River can't finish its voyage because of low water levels, according to a statement from the company on Thursday. "Unusually low water ...

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase ...